Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Article first published online: 3 JAN 2013
© 2012 John Wiley & Sons A/S
Special Issue: Proceedings of the 6th Paris Hepatitis Conference, International Conference on the Management of Patients with Viral Hepatitis
Volume 33, Issue Supplement s1, pages 105–110, February 2013
How to Cite
Shiffman, M. L. and Benhamou, Y. (2013), Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. Liver International, 33: 105–110. doi: 10.1111/liv.12066
- Issue published online: 3 JAN 2013
- Article first published online: 3 JAN 2013
- hepatitis C virus treatment;
- protease inhibitors;
- polymerase inhibitors;
The current standard of care (SOC) for patients with chronic HCV genotype 1 is a combination of either boceprevir or telaprevir with peginterferon (PEG-IFN) and ribavirin (RBV). Although it is effective in a high percentage of patients, this treatment is associated with significant adverse events (AEs). The next generation of protease inhibitors, simeprevir and faldaprevir, will also be used with PEG-IFN/RBV. Interferon-free therapy with sofosbuvir appears promising and on the horizon for patients with genotypes 2 and 3, but may still be many years away for patients with HCV genotype 1. The factors which should be considered when deciding whether to treat a patient with HCV and mild fibrosis with the current SOC now, or to delay treatment until less toxic and/or more effective therapy is available is discussed.